share_log

恒瑞医药(600276.SH):羟乙磺酸达尔西利片、HRS8807片临床试验获批

Hengrui Pharmaceutical (600276.SH): Clinical trials of darsilil hydroxyethanesulfonate tablets and HRS8807 tablets approved

Zhitong Finance ·  Apr 12 04:38

Hengrui Pharmaceutical (600276.SH) issued an announcement. The company and its subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd. received the national drug...

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. The company and its subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd. have received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for darsilane sulfonate tablets and HRS8807 tablets, which will conduct clinical trials in the near future.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment